Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Shannon M. Liudahl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8587-8204; OpenAlex author ID A5052117035. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 7

  1. Correction: Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognosti… Co-author DOI 10.1158/0008-5472.can-24-2929↗
  2. Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers. Co-author DOI 10.1158/0008-5472.can-22-1190↗
  3. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  4. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  5. Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma. First author DOI 10.1200/po.20.00287↗
  6. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-12657-w↗
  7. Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-13151-z↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lisa M. Coussens · 7 shared papers, 2019–2024 · strength 0.87
  2. Elizabeth M. Jaffee · 4 shared papers, 2021–2024 · strength 0.59
  3. Haoyang Mi · 2 shared papers, 2022–2024 · strength 0.41
  4. Aleksander S. Popel · 2 shared papers, 2022–2024 · strength 0.41
  5. Terry K. Morgan · 3 shared papers, 2019–2021 · strength 0.27
  6. Jason M. Link · 2 shared papers, 2021 · strength 0.20
  7. Rosalie C. Sears · 2 shared papers, 2021 · strength 0.20
  8. Andressa Dias Costa · 2 shared papers, 2021 · strength 0.18
  9. Sara A. Väyrynen · 2 shared papers, 2021 · strength 0.18
  10. Robert H. Vonderheide · 2 shared papers, 2021 · strength 0.18
  11. Brian Matthew Wolpin · 2 shared papers, 2021 · strength 0.18
  12. Jonathan Andrew Nowak · 2 shared papers, 2021 · strength 0.18
  13. Kevin G. Burfeind · 2 shared papers, 2019 · strength 0.16
  14. Brennan G. Olson · 2 shared papers, 2019 · strength 0.16
  15. Katherine R. Pelz · 2 shared papers, 2019 · strength 0.16
  16. H. Carlo Maurer · 2 shared papers, 2019 · strength 0.16
  17. Katherine A. Michaelis · 2 shared papers, 2019 · strength 0.16
  18. Xinxia Zhu · 2 shared papers, 2019 · strength 0.16
  19. Daniel L. Marks · 2 shared papers, 2019 · strength 0.16
  20. Kenneth P. Olive · 2 shared papers, 2019 · strength 0.16
  21. Charles D. Lopez · 1 shared paper, 2021 · strength 0.11
  22. David Lawrence Bajor · 1 shared paper, 2021 · strength 0.09
  23. Katelyn T. Byrne · 1 shared paper, 2021 · strength 0.09
  24. Mark H. O’Hara · 1 shared paper, 2021 · strength 0.09
  25. Elena Gabriela Chiorean · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.